FC
EW icon

Fairscale Capital’s Edwards Lifesciences EW Stock Holding History

Fairscale Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.88K Hold
36
– – ﹤0.01% 368
2025
Q4 		$3.07K Hold
36
– – ﹤0.01% 357
2025
Q3 		$2.8K Hold
36
– – ﹤0.01% 389
2025
Q2 		$2.85K Buy
+36
New +$2.69K ﹤0.01% 383

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fairscale Capital's EW Position: Q1 2026 in Review

Fairscale Capital held its Edwards Lifesciences (EW) position steady in Q1 2026 at 36 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #368.

Fairscale Capital first reported a position in EW in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.07K in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Fairscale Capital held 36 shares of Edwards Lifesciences worth $2.88K as of Q1 2026.
  • Fairscale Capital left its Edwards Lifesciences share count unchanged in Q1 2026.
  • Edwards Lifesciences made up ﹤0.01% of Fairscale Capital's portfolio in Q1 2026, its #368 holding.
  • Fairscale Capital first reported a position in Edwards Lifesciences in Q2 2025 and has held it in 4 quarters since.
  • Fairscale Capital's Edwards Lifesciences position peaked at $3.07K in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.